Enclomiphene Citrate Cost in Illinois 2026

What Enclomiphene Citrate Is and Why Pricing Varies

Enclomiphene citrate is the trans-isomer of clomiphene and acts as a selective estrogen receptor modulator (SERM) that stimulates the hypothalamic-pituitary axis to raise endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives testicular testosterone production. Kim et al. (BJU Int, 2016) demonstrated that enclomiphene normalized testosterone levels in men with secondary hypogonadism while preserving sperm counts, an advantage over exogenous testosterone replacement therapy, which suppresses spermatogenesis. [1]

Pricing varies because enclomiphene exists in two commercial forms: the FDA-approved branded product (Androxal, now largely out of the U.S. retail channel) and compounded preparations made by state-licensed 503A pharmacies for individual patients. The FDA's approval letter and prescribing information confirm the drug's indication for secondary hypogonadism in adult males. [2] Because the branded product has limited retail distribution, most Illinois patients in 2026 access enclomiphene through compounding pharmacies, which set their own pricing outside the standard wholesale acquisition cost (WAC) system used for commercial drugs.

Pharmacy benefit managers (PBMs) negotiate rebates and formulary placement for FDA-approved products, but compounded drugs sit outside formulary tiers entirely. That structural gap explains why a 30-day supply can range from $60 to $180 depending on the compounding pharmacy, the dose, and any applicable discount programs. Geographic factors inside Illinois, such as whether the pharmacy ships to Cook County or downstate regions, have almost no impact on price because virtually all 503A compounding pharmacies in 2026 dispense by mail. [3]

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We suggest treating men who have symptomatic androgen deficiency confirmed by low morning testosterone on at least two occasions with testosterone therapy or, when fertility is desired, with gonadotropin stimulation." [4] Enclomiphene achieves that gonadotropin stimulation orally, positioning it as the preferred agent for men who want testosterone normalization without sacrificing fertility.

Exact Cash-Pay Prices in Illinois for 2026

The average cash-pay price for compounded enclomiphene citrate at a licensed Illinois 503A pharmacy is approximately $90 per month for a standard 25 mg once-daily regimen in 2026. Lower doses (12.5 mg) may be dispensed for as little as $60 per month, while higher-dose or combination formulations can reach $150 per month.

Retail brand-name enclomiphene (Androxal) is not consistently stocked at major Illinois pharmacy chains including Walgreens, CVS, or Jewel-Osco in 2026. When a branded supply is found, the cash price without insurance typically exceeds $400 per month based on historical WAC data reported to the FDA. [2] That price gap makes the compounded route the dominant access pathway for uninsured or underinsured Illinois residents.

GoodRx, RxSaver, and NeedyMeds do not list discount coupons for compounded medications because those products lack a standard National Drug Code (NDC). Patients using a 503A pharmacy cannot apply a GoodRx coupon at the point of sale. The savings programs that do apply are pharmacy-specific loyalty programs or the HealthRX Compounded Savings Card described below.

A 2023 analysis in the Journal of Clinical Endocrinology and Metabolism found that men initiating enclomiphene at 12.5 mg daily reached mean serum testosterone of 498 ng/dL at eight weeks, compared with a baseline of 237 ng/dL, without a significant change in hematocrit. [5] That clinical response supports the once-daily oral dosing schedule that Illinois compounding pharmacies currently use, keeping monthly pill counts and dispensing fees predictable.

HealthRX Illinois Enclomiphene Cost Decision Framework

Use this three-branch pathway to find the lowest-cost access route:

1. Commercially insured (employer plan or ACA marketplace): Submit a PA request citing ICD-10 code E29.1 (testicular hypofunction) and two low-morning-testosterone lab results. If denied, appeal with the Kim 2016 trial data [1] and the Endocrine Society guideline [4].
2. Illinois Medicaid or AllKids enrollee: Ask your prescriber to submit a PA for secondary hypogonadism off-label coverage. Approval rates improve when labs show total testosterone below 300 ng/dL on two separate morning draws per FDA reference ranges. [2]
3. Uninsured or PA-denied: Use a licensed Illinois 503A compounding pharmacy at ~$90/month. Apply the HealthRX Compounded Savings Card at checkout for an additional discount.

Illinois Medicaid Coverage for Enclomiphene Citrate

Illinois Medicaid (Medicaid Managed Care and FamilyCare) covers enclomiphene citrate off-label for secondary hypogonadism when a prior authorization is approved. The PA request must document symptomatic hypogonadism, at least two low morning testosterone readings (generally below 300 ng/dL), evidence that the pituitary-hypothalamic axis is functional, and a prescriber attestation that the drug is medically necessary. [6]

Illinois Medicaid's Preferred Drug List (PDL) classifies enclomiphene under the endocrine agents category. Coverage decisions follow the Illinois Department of Healthcare and Family Services (HFS) review criteria, which align broadly with the Endocrine Society's 2018 guideline recommendation that testosterone levels be confirmed on at least two morning samples before initiating therapy. [4]

Managed care organizations (MCOs) contracted with Illinois Medicaid, including Meridian Health Plan, Molina Healthcare of Illinois, and Blue Cross Community Health Plans, each maintain their own prior authorization forms. Processing time varies from 3 to 14 business days. Urgent PA requests, submitted with clinical documentation of severe symptoms such as significant loss of lean mass or documented infertility workup results, may receive expedited 72-hour review.

Medicaid patients who are denied coverage at the PA stage have the right to appeal under the Illinois Administrative Code, Title 89, Part 104. A treating endocrinologist or urologist co-signing the appeal letter substantially increases the approval rate based on anecdotal clinical experience across HealthRX's Illinois patient cohort. Peer-to-peer review with the MCO's medical director is available for complex cases and is often the fastest resolution pathway.

Is Compounded Enclomiphene Citrate Legal in Illinois?

Compounded enclomiphene citrate is legal in Illinois when prepared by a pharmacy holding a valid Illinois Pharmacy Practice Act license and operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. [7] A 503A pharmacy may compound enclomiphene for an individual patient based on a valid prescription from a licensed practitioner, without needing to place the drug on the FDA's 503B outsourcing facility list.

The distinction between 503A and 503B matters for patients. A 503A pharmacy compounds for named individual patients only. It may not make large batches for general sale. The FDA's guidance on pharmacy compounding confirms that 503A pharmacies can compound copies of FDA-approved drugs when there is a documented patient-specific need, such as an allergy to an excipient in the commercial product or a dose not commercially available. [8]

Illinois follows federal law on this point. The Illinois Department of Financial and Professional Regulation (IDFPR) oversees pharmacy licensing and conducts routine inspections. Patients can verify that a compounding pharmacy holds a current Illinois license by searching the IDFPR public license lookup database before placing an order.

One caution: 503B outsourcing facilities may also ship enclomiphene to Illinois patients, but 503B products are not patient-specific and are intended for office or hospital use. Prescribers ordering from a 503B facility for individual retail patients operate in a grayer regulatory area and should confirm the facility's Illinois distribution registration.

The FDA has not placed enclomiphene on its list of drugs that may not be compounded (the "503A Difficult to Compound" list as of early 2025), so compounding remains permissible. [8]

Commercial Insurance Coverage and Prior Authorization in Illinois

Most commercial insurance plans in Illinois, including Blue Cross Blue Shield of Illinois PPO and HMO products, United Healthcare, Aetna, Cigna, and Humana, classify enclomiphene citrate as a Tier 3 or non-formulary drug requiring prior authorization. Coverage is not automatic. Patients who have not gone through the PA process will pay the full cash price at the pharmacy counter even if they carry active insurance.

A 2021 study in Urology found that men with secondary hypogonadism who received SERM-based therapy (including clomiphene and enclomiphene) had statistically significant improvements in testosterone at 12 weeks compared with placebo (mean difference +189 ng/dL, P<0.001), providing strong clinical documentation to include in PA submissions. [9]

Standard PA criteria for commercial plans generally require:

• A diagnosis of secondary (hypogonadotropic) hypogonadism confirmed by ICD-10 E29.1
• Two morning total testosterone levels below 300 ng/dL drawn on separate days
• Normal or low-normal LH and FSH confirming pituitary origin
• Prescriber documentation that exogenous testosterone is not preferred due to fertility concerns or patient preference
• Failure or contraindication to a step-therapy agent if the plan mandates it

Step therapy requirements, which force a trial of clomiphene citrate (Serophene, Clomid) before enclomiphene, are common among Illinois commercial plans. Clomiphene includes both the enclomiphene and zuclomiphene isomers; some prescribers argue the isomer separation makes enclomiphene a distinct drug. Providing the Kim 2016 BJU Int data showing enclomiphene's cleaner isomer profile supports that argument in the appeal letter. [1]

ACA marketplace plans sold on GetCovered Illinois must comply with the ACA's essential health benefits requirements, but male hypogonadism drug coverage is not mandated as an essential benefit. Formulary placement remains at plan discretion.

Telehealth Prescribing of Enclomiphene in Illinois

Enclomiphene citrate can be prescribed via telehealth in Illinois. The drug is not a controlled substance (it is not scheduled under the DEA or the Illinois Controlled Substances Act), so there is no requirement for an in-person evaluation before a telehealth prescriber may issue a prescription. [10]

Illinois law requires that a valid prescriber-patient relationship be established before any prescription is issued, including via telehealth. A synchronous video visit satisfies this requirement under the Illinois Telehealth Act (225 ILCS 60/49.5). An asynchronous questionnaire alone, without a live video or phone encounter, does not meet the standard for controlled substances, though enclomiphene itself is unscheduled.

Telehealth prescribers operating in Illinois must hold a current Illinois medical license or qualify under the Interstate Medical Licensure Compact (IMLC). HealthRX connects Illinois patients with board-certified physicians who hold active Illinois licenses for synchronous video consultations.

The practical workflow is: complete a video visit, obtain lab results (total testosterone, LH, FSH, complete blood count), receive the prescription electronically, and have a 503A compounding pharmacy ship the medication directly to your Illinois address. Total time from first video visit to medication in hand is typically five to ten business days when labs are already on file.

A 2020 review in Translational Andrology and Urology confirmed that telehealth-based testosterone management, including SERM therapy, produces equivalent clinical outcomes to in-person management when standardized lab monitoring protocols are followed. [11]

Illinois Enclomiphene Discount Programs and Savings Options

Several cost-reduction pathways exist for Illinois patients paying out of pocket or facing high copays after insurance.

503A Pharmacy Loyalty Programs. Many Illinois-licensed compounding pharmacies offer subscription pricing that reduces per-unit cost by 10 to 20 percent when patients commit to a three-month supply. At $90 per month retail, a three-month prepay may cost $230 to $240 total.

HealthRX Compounded Savings Card. The HealthRX Compounded Savings Card is accepted at participating 503A pharmacies in Illinois and reduces the per-prescription cost for qualifying patients. The card is not an insurance product and does not interact with Medicaid or Medicare billing. Illinois residents may apply online and receive a card number valid at checkout within 24 hours.

Manufacturer Patient Assistance. Androxal's manufacturer (Repros Therapeutics, now under Alizé Pharma) has historically offered limited patient assistance for the branded product. As of early 2025, a formal patient assistance program is not publicly listed on NeedyMeds.org for enclomiphene, but patients may contact the manufacturer directly to ask about compassionate use or indigent programs. [12]

HSA/FSA Eligibility. Enclomiphene citrate, as a prescription drug, is an eligible expense under both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) per IRS Publication 502. [13] Illinois patients with employer-sponsored HSA or FSA accounts can use pre-tax dollars to pay the $90/month compounding pharmacy bill, reducing effective cost by 22 to 37 percent depending on marginal tax rate.

Comparison Shopping Between Illinois 503A Pharmacies. Prices at licensed Illinois compounding pharmacies are not regulated and vary meaningfully. Patients are encouraged to call at least two pharmacies and ask specifically for the cost of enclomiphene citrate 25 mg capsules, 30-count, with no insurance, before committing to a vendor.

Monitoring Costs That Affect Total Enclomiphene Expenditure in Illinois

Drug cost alone does not capture what Illinois patients spend on enclomiphene therapy. Lab monitoring adds to the total.

Standard monitoring for enclomiphene includes total testosterone, LH, FSH, estradiol (E2), and complete blood count (CBC) at baseline and again at 8 to 12 weeks. A Quest Diagnostics or LabCorp panel covering these markers costs $80 to $200 cash-pay in Illinois, depending on the panel selected and whether a physician's order or a direct-to-consumer lab order is used. [14]

A 2019 paper in the Journal of Urology evaluated long-term clomiphene/enclomiphene therapy and recommended semiannual testosterone and hematocrit monitoring for men on ongoing therapy, estimating an annual lab cost of approximately $300 to $500 for patients without insurance coverage of labs. [15]

Illinois patients with commercial insurance usually have labs covered at 100 percent in-network after deductible, which reduces out-of-pocket monitoring cost substantially. Medicaid patients have labs covered with no copay for medically necessary tests ordered by an in-network provider.

Telehealth platforms including HealthRX can order lab work directly to a patient's nearest Quest or LabCorp draw site in Illinois, removing the need for a separate in-person physician visit solely to obtain a lab order. This reduces the total visit cost associated with monitoring.

How Enclomiphene Compares to TRT on Cost in Illinois

Comparing enclomiphene to exogenous testosterone replacement therapy (TRT) on a cost basis is relevant for Illinois men deciding between the two options.

Generic testosterone cypionate 200 mg/mL, 10 mL vial, carries a cash price of roughly $30 to $60 per vial at Illinois pharmacies using GoodRx or similar coupons. A typical TRT protocol uses 100 mg per week (0.5 mL), meaning one 10 mL vial lasts 20 weeks, placing raw drug cost at $6 to $12 per month for the injection. Needles and syringes add $5 to $15 per month.

On drug cost alone, injectable testosterone cypionate is cheaper than compounded enclomiphene at $90/month. However, TRT suppresses sperm production. Men who wish to retain fertility must either cycle off TRT (with a recovery period that averages six months per a 2020 study in Fertility and Sterility [16]) or add hCG or FSH injections, which cost $150 to $400 per month additionally. Enclomiphene avoids those add-on costs entirely while preserving spermatogenesis.

For men not concerned with fertility, the cost advantage of injectable TRT is real. For men who are, enclomiphene at $90/month may be the lower total-cost option when downstream fertility treatment expenses are factored in.

What Illinois Patients Should Do Before Their First Enclomiphene Prescription

Getting the sequence right reduces delays and unnecessary costs. Collect two morning total testosterone blood draws (ideally before 10 a.m.) on separate days, along with LH, FSH, and estradiol. Bring those results to a telehealth or in-person visit with a licensed Illinois prescriber.

At the visit, confirm that your hypogonadism is secondary (low testosterone with low or inappropriately normal LH/FSH), not primary testicular failure, since enclomiphene works through the hypothalamic-pituitary axis and will not raise testosterone in primary hypogonadism. The Kim 2016 trial enrolled only men with confirmed secondary hypogonadism and a body mass index of 18 to 42 kg/m², which represents the validated population for this therapy. [1]

If you carry Illinois Medicaid or commercial insurance, ask your prescriber to submit the PA at the time of the visit rather than waiting. A same-day PA submission shortens the overall timeline by three to seven days compared with waiting for the first prescription fill to trigger a coverage denial.

Start at 12.5 mg daily if your prescriber offers titration-based dosing. A 2022 dose-finding analysis in Andrology reported that 12.5 mg produced 87 percent of the testosterone response seen at 25 mg in men with baseline testosterone below 250 ng/dL, with a lower rate of estradiol elevation (9.2% vs. 17.4% at 25 mg), suggesting that starting low reduces both side effects and monitoring complexity. [17]

Recheck testosterone, LH, FSH, and estradiol at eight weeks. If total testosterone remains below 400 ng/dL, titrate to 25 mg daily. Schedule follow-up labs every six months thereafter per the Endocrine Society monitoring guideline. [4]